Ery — Compare Prices at US & Canada Pharmacies

Ery is a brand of topical erythromycin — pre-soaked pledgets (pads) that deliver a 2% erythromycin solution directly to acne-affected skin rather than through the bloodstream. It's a macrolide, the same antibiotic class as oral erythromycin and azithromycin, but applied topically it works locally: it slows the growth of Cutibacterium acnes (formerly Propionibacterium acnes), the bacteria that colonize clogged pores and drive inflammatory acne lesions, and it has a mild anti-inflammatory effect on the skin itself.

Because the drug stays largely on the skin's surface rather than being absorbed systemically, the serious warnings attached to oral erythromycin — QT prolongation, liver enzyme elevation, interactions with theophylline or statins — are not meaningfully relevant to this topical formulation; they belong to the oral tablet version of the drug, not the pad. The tradeoff that does matter clinically is resistance: C. acnes resistance to topical erythromycin has become widespread over the past two decades, which is why dermatologists increasingly pair it with benzoyl peroxide (which reduces resistance development) or reserve it as a second-line option behind topical clindamycin or retinoids.

Ery pads are for external use only — apply to clean, dry skin once or twice daily, avoiding the eyes, mouth, and mucous membranes. Mild dryness, peeling, or irritation is common and usually improves as skin adjusts; a moisturizer can help. Like most topical antibiotics, it's meant for a defined course rather than indefinite daily use, both to limit resistance and because efficacy tends to plateau after several weeks.

Contraindications

CONTRAINDICATIONS Erythromycin is contraindicated in patients with known hypersensitivity to this antibiotic. Erythromycin is contraindicated in patients taking terfenadine, astemizole, cisapride, pimozide, ergotamine, or dihydroergotamine. (See PRECAUTIONS – Drug Interactions .) Do not use erythromycin concomitantly with HMG CoA reductase inhibitors (statins) that are extensively metabolized by CYP 3A4 (lovastatin or simvastatin), due to the increased risk of myopathy, including rhabdomyolysis.

Warnings

WARNINGS Hepatotoxicity There have been reports of hepatic dysfunction, including increased liver enzymes, and hepatocellular and/or cholestatic hepatitis, with or without jaundice, occurring in patients receiving oral erythromycin products. QT Prolongation Erythromycin has been associated with prolongation of the QT interval and infrequent cases of arrhythmia. Cases of torsades de pointes have been spontaneously reported during postmarketing surveillance in patients receiving erythromycin. Fatalities have been reported.

Known drug interactions

Drug Interactions Theophylline Erythromycin use in patients who are receiving high doses of theophylline may be associated with an increase in serum theophylline levels and potential theophylline toxicity. In case of theophylline toxicity and/or elevated serum theophylline levels, the dose of theophylline should be reduced while the patient is receiving concomitant erythromycin therapy. There have been published reports suggesting that when oral erythromycin is given concurrently with theophylline there is a decrease in erythromycin serum concentrations of approximately 35%. The mechanism by which this interaction occurs is unknown.

Pregnancy & breastfeeding

Pregnancy Teratogenic Effects There is no evidence of teratogenicity or any other adverse effect on reproduction in female rats fed erythromycin base by oral gavage at 350 mg/kg/day (approximately twice the maximum recommended human dose on a body surface area) prior to and during mating, during gestation, and through weaning.